Condition: Glioblastoma, IDH-wildtype · Glioblastoma · Glioblastoma Multiforme · Sponsor: Orbus Therapeutics, Inc.
The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.
This description comes directly from the study's public registry record.
Monika Varga · 6506569424 · monika.varga@orbustherapeutics.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Withdrawn |
| Henry Ford Hospital | Detroit, Michigan, United States | Recruiting |
| Columbia University Medical Center - Herbert Irving Pavilion | New York, New York, United States | Recruiting |
| Duke University | Durham, North Carolina, United States | Recruiting |
| The Cleveland Clinic | Cleveland, Ohio, United States | Recruiting |
| Brown University Health/Rhode Island Hospital | Providence, Rhode Island, United States | Recruiting |
| UT MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| University of Utah, Huntsman Cancer Institute | Salt Lake City, Utah, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05879367